Most Recent
AstraZeneca has denied claims by Pharmacor that a patent for its diabetes drug Forxiga is invalid and that an extension of the patent's term was wrongly granted.
China-based Hytera Communications wants the High Court to overturn a finding that it stole Motorola's source code for its digital mobile radios, arguing the appeal raises important issues about how "substantial part" should be assessed under the Copyright Act.
Pfizer has lost a patent infringement lawsuit against Samsung Bioepis over the generic version of its blockbuster autoimmune drug Enbrel, with a judge finding all but one of the patent's claims is invalid.
AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.
Pharmacor has accused AstraZeneca of launching a royal commission into emails with its lawyers as AstraZeneca opposes the generic drug maker's bid to amend its pleading in a patent case over diabetes drug Forxiga.
AstraZeneca can inspect Pharmacor's emails to verify its claim that the merits of its challenge to a patent extension for blockbuster diabetes drug Forxiga were not appreciated at an earlier time, with a judge finding Pharmacor had waived privilege.
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.
The High Court has agreed to hear Otsuka's appeal of a decision that revoked its Abilify patent extension, which Otsuka argued would “lead to a groundswell of court proceedings”.